Rose, Angela McPozo Sanchez, FranciscoMartínez-Baz, IvánMazagatos, ClaraBossuyt, NathalieCauchi, John PaulPetrović, GorankaLoghin, Isabela IVaikutytė, RobertaBuda, SilkeMachado, AusendaDuffy, RóisínOroszi, BeatrixHoward, JenniferEcheverria, AitziberAndreu, CristinaBarbezange, CyrilDžiugytė, AušraNonković, DianaPopescu, Corneliu-PetruMajauskaite, FaustaTolksdorf, KristinGomez, VerónicaDomegan, LisaHorváth, Judit KrisztinaCastilla, JesúsGarcía, MiriamDemuyser, ThomasBorg, Maria-LouiseTabain, IrenaLazar, MihaelaKubiliute, IevaDürrwald, RalfGuiomar, RaquelO'Donnell, JoanKristóf, KatalinNicolay, NathalieBacci, SabrinaKissling, EstherEBIS SARI VE network team2024-03-222024-03-222024-02Influenza Other Respir Viruses. 2024 Feb;18(2):e13255.http://hdl.handle.net/20.500.12105/19060We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.engVoRhttp://creativecommons.org/licenses/by/4.0/Influenza, HumanInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesPneumoniaAdultHumansSeasonsInfluenza A Virus, H3N2 SubtypeCase-Control StudiesVaccine EfficacyEuropeHospitalizationHospitalsVaccinationAtribución 4.0 Internacional38403302182e1325510.1111/irv.132551750-2659Influenza and other respiratory virusesopen access